Abstract
Isoniazid resistant Mycobacterium tuberculosis (Hr-TB) is the most frequently encountered TB resistance phenotype in North America but limited data exist on the effectiveness of current therapeutic regimens. Ineffective treatment of Hr-TB increases patient relapse and anti-mycobacterial resistance, specifically MDR-TB. We undertook a multi-centre, retrospective review of culture-positive Hr-TB patients in Alberta, Canada (2007-2017). We assessed incidence and treatment outcomes, with a focus on fluoroquinolone (FQ)-containing regimens, to understand the risk of unsuccessful outcomes. Rates of Hr-TB were determined using the mid-year provincial population and odds of unsuccessful treatment was calculated using a Fisher's Exact test. One hundred eight patients of median age 37 years (IQR: 26-50) were identified with Hr-TB (6.3%), 98 of whom were able to be analyzed. Seven percent reported prior treatment. Rate of foreign birth was high (95%), but continent of origin did not predict Hr-TB (p = 0.47). Mean compliance was 95% with no difference between FQ and non-FQ regimens (p = 1.00). Treatment success was high (91.8%). FQ-containing regimens were frequently initiated (70%), with no difference in unsuccessful outcomes compared to ...Continue Reading
References
Nov 13, 2007·Journal of Gastroenterology and Hepatology·Alma TostmannRichard Dekhuijzen
Oct 17, 2008·PloS One·Israel HershkovitzMark Spigelman
Dec 18, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Adithya CattamanchiPayam Nahid
Jan 28, 2010·PLoS Medicine·Dick MenziesChristian Lienhardt
Mar 30, 2010·The Journal of Infection·Didi BangVibeke Østergaard Thomsen
Jan 1, 2010·Tuberculosis Research and Treatment·Justin T Denholm, Emma S McBryde
Jun 8, 2013·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·C-C ShuL-N Lee
Jul 31, 2013·Tuberculosis·Igor MokrousovNalin Rastogi
Apr 5, 2014·TheScientificWorldJournal·Zhili LiuShanhu Huang
Jul 6, 2014·QJM : Monthly Journal of the Association of Physicians·M L MunangM Dedicoat
Feb 1, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J-Y ChienC-J Yu
Nov 4, 2015·Antimicrobial Agents and Chemotherapy·Hyun LeeWon-Jung Koh
Apr 3, 2016·The Lancet Infectious Diseases·Robert S WallisAlimuddin Zumla
Jul 28, 2016·PloS One·Hyun Woo LeeChang-Hoon Lee
Aug 10, 2016·Cold Spring Harbor Perspectives in Medicine·Michael J TrimbleRobert E W Hancock
Nov 21, 2016·The Lancet Infectious Diseases·Medea GegiaDick Menzies
Mar 28, 2017·The Lancet. Respiratory Medicine·Keertan DhedaRobin M Warren
Sep 6, 2017·BMC Infectious Diseases·Kamila RomanowskiJames C Johnston
Mar 2, 2018·Annals of the American Thoracic Society·Max O'Donnell
Mar 30, 2018·The Lancet. Respiratory Medicine·Federica FregoneseDick Menzies
May 29, 2018·Tuberculosis Research and Treatment·C PadmapriyadarsiniPrathap Tharyan
Dec 5, 2018·PloS One·Jose Gabriel Cornejo GarciaDavid A J Moore
Aug 3, 2019·The European Respiratory Journal·Helen R StaggUNKNOWN London INH-R TB study group
Sep 14, 2019·Journal of the American College of Cardiology·Mahyar EtminanJames M Brophy
Oct 12, 2019·The European Respiratory Journal·Roland Diel, Neil W Schluger
Nov 16, 2019·American Journal of Respiratory and Critical Care Medicine·Payam NahidBarbara Seaworth
Citations
Nov 20, 2020·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·M A Abo-KadoumJianping Xie
Feb 17, 2021·PloS One·Brett D EdwardsDina Fisher
Feb 20, 2021·Infection and Drug Resistance·Wubet Birhan YigzawBelay Tessema